Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience, reported insider trading activity on June 20, 2025. The transaction involved a mandatory "sell to cover" of 1,678 shares of Common Stock at $35.755 per share to satisfy tax withholding obligations related to vesting Restricted Stock Units.
Following the transaction, Leproust maintains direct ownership of 645,782 shares of Common Stock. Additionally, she holds several employee stock options:
- 150,879 options at $8.82 (expires 09/28/2027)
- 266,539 options at $26.66 (expires 11/18/2028)
- 131,290 options at $23.33 (expires 10/23/2029)
- 64,950 performance-based options at $67.85 (expires 08/31/2030)
The reported sale was not discretionary but rather mandated by the company's equity incentive plan requirements for tax withholding purposes.